These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 3125972)

  • 1. Nephrotoxicity and carcinogenic risk of cis-platin (CDDP) prevented by sodium 2-mercaptoethane-sulfonate (Mesna): experimental results.
    Kempf SR; Ivankovic S
    Cancer Treat Rev; 1987 Dec; 14(3-4):365-72. PubMed ID: 3125972
    [No Abstract]   [Full Text] [Related]  

  • 2. Effective prevention of the nephrotoxicity of cis-platin (CDDP) by administration of sodium 2-mercaptoethane-sulfonate (MESNA) in rats.
    Kempf SR; Ivankovic S; Wiessler M; Schmähl D
    Br J Cancer; 1985 Dec; 52(6):937-9. PubMed ID: 3935152
    [No Abstract]   [Full Text] [Related]  

  • 3. Cisplatin-induced loss of kidney copper and nephrotoxicity is ameliorated by single dose diethyldithiocarbamate, but not mesna.
    DeWoskin RS; Riviere JE
    Toxicol Appl Pharmacol; 1992 Feb; 112(2):182-9. PubMed ID: 1311464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of urinary bladder tumors in cyclophosphamide-treated rats by additional medication with the uroprotectors sodium 2-mercaptoethane sulfonate (mesna) and disodium 2,2'-dithio-bis-ethane sulfonate (dimesna).
    Habs MR; Schmähl D
    Cancer; 1983 Feb; 51(4):606-9. PubMed ID: 6401591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prevention of urotoxic actions of cyclophosphamide and ifosfamide by dimesna (preliminary communication) (author's transl)].
    Brock N; Stekar J
    Arzneimittelforschung; 1982; 32(5):486-7. PubMed ID: 6809014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies on hemotoxicity of cyclophosphamide, doxorubicin and cis-diamminodichloroplatinum combined with sodium-2-mercaptoethane sulfonate.
    Lerza R; Bogliolo G; Mencoboni M; Saviane A; Pannacciulli I
    Tumori; 1988 Jun; 74(3):333-7. PubMed ID: 3135644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prevention of tumor formation in the bladder by sodium-2-mercaptoethane sulfonate (mesna). Experimental studies and clinical consequences].
    Schmähl D; Habs M; Tacchi AM
    Urologe A; 1984 Sep; 23(5):291-6. PubMed ID: 6438859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of cyclophosphamide cystitis with 2-mercaptoethane sodium sulfonate: a histologic study.
    Freedman A; Ehrlich RM; Ljung BM
    J Urol; 1984 Sep; 132(3):580-2. PubMed ID: 6433044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-2-mercaptoethanesulfonate (MESNA) and ifosfamide nephrotoxicity.
    Hilgard P; Burkert H
    Eur J Cancer Clin Oncol; 1984 Nov; 20(11):1451-2. PubMed ID: 6437825
    [No Abstract]   [Full Text] [Related]  

  • 10. The use of sodium 2-mercaptoethane sulfonate to prevent cyclophosphamide cystitis.
    Ehrlich RM; Freedman A; Goldsobel AB; Stiehm ER
    J Urol; 1984 May; 131(5):960-2. PubMed ID: 6423841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Failure of 2-mercaptoethane sulphonate sodium (mesna) to protect against ifosfamide nephrotoxicity.
    Sangster G; Kaye SB; Calman KC; Dalton JF
    Eur J Cancer Clin Oncol; 1984 Mar; 20(3):435-6. PubMed ID: 6423391
    [No Abstract]   [Full Text] [Related]  

  • 12. Malignant pleural mesothelioma: phase II pilot study of ifosfamide and mesna.
    Alberts AS; Falkson G; Van Zyl L
    J Natl Cancer Inst; 1988 Jul; 80(9):698-700. PubMed ID: 3131539
    [No Abstract]   [Full Text] [Related]  

  • 13. Mesna does not reduce cisplatin induced nephrotoxicity in the rat.
    Millar BC; Siddik ZH; Millar JL; Jinks S
    Cancer Chemother Pharmacol; 1985; 15(3):307-9. PubMed ID: 3931929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna).
    Brock N; Pohl J; Stekar J; Scheef W
    Eur J Cancer Clin Oncol; 1982 Dec; 18(12):1377-87. PubMed ID: 6819957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction between cisplatin and mesna in mice.
    Dorr RT; Lagel K
    J Cancer Res Clin Oncol; 1989; 115(6):604-5. PubMed ID: 2514188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New treatments for urogenital toxicity of anti-neoplastic chemotherapy].
    Shibuya M; Hirosawa A; Niitani H
    Gan To Kagaku Ryoho; 1990 Apr; 17(4 Pt 2):950-6. PubMed ID: 2111664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ifosfamide-induced subclinical tubular nephrotoxicity despite mesna.
    Goren MP; Wright RK; Horowitz ME; Pratt CB
    Cancer Treat Rep; 1987 Feb; 71(2):127-30. PubMed ID: 2879626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of fosfomycin, mesna, and sodium thiosulfate on the toxicity and antitumor activity of cisplatin.
    Wagner T; Kreft B; Bohlmann G; Schwieder G
    J Cancer Res Clin Oncol; 1988; 114(5):497-501. PubMed ID: 3141427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclophosphamide-induced water intoxication: treatment with fluid restriction and 2-mercaptoethane sulfonate.
    Haas A; Chin T; Stiehm ER
    Am J Dis Child; 1986 Nov; 140(11):1094-5. PubMed ID: 3094362
    [No Abstract]   [Full Text] [Related]  

  • 20. Arginine 2-mercaptoethane sulfonate and sodium 2-mercaptoethane sulfonate: a comparative study of their effects upon tumour cells.
    Magnolfi Zipoli G; D'Ancona S; Berti T
    Drugs Exp Clin Res; 1988; 14(7):473-8. PubMed ID: 3149236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.